These peptides act on appetite, satiety, gastric emptying, and metabolic signaling. They don't produce the reinforcement-driven escalation pattern that defines addiction. People don't crave the peptide more over time, and they don't need higher doses for the same reward effect.

A 2024 systematic review on GLP-1 and reward and motivation pathways found something close to the opposite of an addictive pattern: GLP-1 signaling appears to modulate craving and reward toward less compulsive consumption of food, alcohol, and other substances.

Research on GLP-1 peptides in alcohol-use disorder and substance-use disorder is active and growing.

"I'm scared to stop taking it" isn't addiction. It's a different feeling, and naming it matters. The fear is usually about appetite returning, the structure of the peptide ending, and the weight coming back. That's a real concern for maintenance, but it isn't a peptide-craving signal in the body.

The discontinuation experience deserves a plan: a maintenance system that doesn't depend on the peptide, ongoing clinician contact during the transition, and an honest expectation that maintenance is its own work.